Stock comparison
Incyte
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
INCY
Incyte
Market cap
$20.04B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | INCY | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 57C | 69B | LMAT |
| Benjamin Graham | 63C | 81A | LMAT |
| Philip Fisher | 51C | 73B | LMAT |
| Peter Lynch | 40D | 59C | LMAT |
| Joel Greenblatt | 35D | 48D | LMAT |
| Charlie Munger | 50C | 60C | LMAT |
| Terry Smith | 56C | 61C | LMAT |
Side-by-side metrics
| Metric | INCY | LMAT |
|---|---|---|
| Market cap | $20.04B | $2.32B |
| P/E (TTM) | 14.0x | 37.1x |
| EV/EBIT | 12.4x | 36.6x |
| ROIC (TTM) | 19.98% | 9.43% |
| Gross margin | 91.86% | 72.39% |
| Net margin | 26.71% | 24.35% |
| Revenue CAGR 5y | 14.55% | 12.75% |
| EPS CAGR 5y | 11.26% | 19.04% |
| Debt / Equity | 0.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
INCY leads on
- Debt / Equity0.0xvs 0.5x+99%
- Market cap$20.04Bvs $2.32B+88%
- EV/EBIT12.4xvs 36.6x+66%
- P/E (TTM)14.0xvs 37.1x+62%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EPS CAGR 5y19.04%vs 11.26%+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.